Sunday 18 October 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.8%, free cash flow grew 43.2% and total debt rose 5.65%, each against the same quarter a year earlier.
1.69
0.02
+1.20%
Follow ABOS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(85.93%) | (96.20%) | (93.23%) | (120.50%) | |
| (65.18%) | (67.07%) | (67.01%) | (72.97%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(121.01%) | (131.54%) | (109.06%) | (152.98%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.04) | (1.91) | (1.67) | (1.27) | |
Free Cash Flow |
(123.74) | (115.63) | (105.54) | (91.79) | |
Capital Expenditures |
(0.09) | (0.09) | — | — | |
| Other line items | |||||
Cash ROIC |
(49.41%) | (52.93%) | (42.74%) | (46.12%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(33.12) | (29.32) | (26.84) | (24.41) | |
Operating CF/Net income |
0.93 | 0.95 | 0.93 | 0.87 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.08 | 0.14 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.04) | (1.91) | (1.67) | (1.27) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates